RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.HER2 amplification in colorectal cancer (CRC) is linked to specific molecular features. These HER2-amplified CRCs are microsatellite stable and show distinct mutation patterns, differing from unamplified tumors.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- HER2 amplification is a key driver in some cancers, but its role and associated molecular features in colorectal cancers (CRCs) remain unclear.
- Understanding these associations is crucial for targeted therapies and improved patient outcomes in CRC management.
Purpose Of The Study
- To determine the prevalence of HER2 amplification in a large cohort of primary colorectal cancers (CRCs).
- To investigate the clinicopathologic features and molecular alterations associated with HER2 amplification in CRCs.
- To compare the molecular landscape of HER2-amplified CRCs with HER2-unamplified CRCs.
Main Methods
- Retrospective analysis of 992 primary colorectal cancer (CRC) patient samples.
- Assessment of HER2 amplification and microsatellite instability (MSI) status.
- Next-generation sequencing (NGS) to analyze somatic mutations in HER2-amplified and unamplified CRCs.
Main Results
- HER2 amplification was detected in 4.1% of CRCs, predominantly in the left colon and rectum.
- HER2-amplified CRCs were exclusively microsatellite stable (MSS).
- HER2-amplified CRCs exhibited lower rates of KRAS mutations (24.4%) but higher rates of TP53 mutations (83%) compared to unamplified CRCs. No BRAF or NRAS mutations were found.
Conclusions
- HER2 amplification in colorectal cancer is associated with microsatellite stability.
- HER2-amplified CRCs present a distinct molecular profile, characterized by a lack of KRAS/NRAS/BRAF mutations and frequent TP53 alterations.
- These findings highlight HER2-amplified CRCs as a unique subtype with potential implications for targeted treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...